Vitaspring Biomedical Announces Leadership and Accountant Changes
| Field | Detail |
|---|---|
| Company | Vitaspring Biomedical Co. Ltd. |
| Form Type | 8-K |
| Filed Date | Aug 11, 2025 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: management-change, auditor-change, filing
TL;DR
Vitaspring Biomedical shakes up leadership and auditor; expect changes.
AI Summary
Vitaspring Biomedical Co. Ltd. announced on August 5, 2025, changes in its certifying accountant, the departure of certain officers, and the appointment of new officers. The company also filed financial statements and exhibits related to these events. The filing details changes in the company's leadership and accounting oversight.
Why It Matters
Changes in certifying accountants and executive officers can signal shifts in financial reporting practices and strategic direction, potentially impacting investor confidence and company operations.
Risk Assessment
Risk Level: medium — Changes in certifying accountants and executive officers can indicate underlying issues or significant strategic shifts, warranting closer investor scrutiny.
Key Players & Entities
- VITASPRING BIOMEDICAL CO. LTD. (company) — Registrant
- Shemn Corp. (company) — Former Company Name
- August 5, 2025 (date) — Date of Earliest Event Reported
- August 11, 2025 (date) — Filing Date
FAQ
What specific reasons were given for the departure of the previous certifying accountant?
The filing indicates a change in the certifying accountant but does not specify the reasons for the departure in the provided text.
Who are the newly appointed officers of Vitaspring Biomedical?
The filing mentions the appointment of certain officers but does not list their names or specific roles in the provided text.
What are the key financial statements being filed with this 8-K?
The filing states that financial statements and exhibits are being filed, but the specific details of these statements are not included in the provided text.
When did Vitaspring Biomedical change its name from Shemn Corp.?
Vitaspring Biomedical Co. Ltd. changed its name from Shemn Corp. on February 10, 2017.
What is the primary business of Vitaspring Biomedical Co. Ltd. according to its SIC code?
According to its SIC code (8731), Vitaspring Biomedical Co. Ltd. is involved in Services-Commercial Physical & Biological Research.
Filing Stats: 1,019 words · 4 min read · ~3 pages · Grade level 10.6 · Accepted 2025-08-11 16:15:36
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value VSBC None Indicate by che
Filing Documents
- vitaspring_8k.htm (8-K) — 29KB
- vitaspring_ex1601.htm (EX-16.1) — 3KB
- image_001.jpg (GRAPHIC) — 9KB
- 0001683168-25-005896.txt ( ) — 210KB
- vsbc-20250805.xsd (EX-101.SCH) — 3KB
- vsbc-20250805_lab.xml (EX-101.LAB) — 33KB
- vsbc-20250805_pre.xml (EX-101.PRE) — 22KB
- vitaspring_8k_htm.xml (XML) — 4KB
01. Changes in Registrant's Certifying Accountant
ITEM 4.01. Changes in Registrant's Certifying Accountant. On August 5, 2025, TAAD LLP ("TAAD") resigned as our independent registered public accounting firm, effective immediately. TAAD's resignation was provided in a written resignation letter dated August 5, 2025. TAAD had served as our independent registered public accounting firm since January 24, 2023. The resignation was the result of new information brought to TAAD's attention. TAAD has advised us that there are no outstanding invoices as of the resignation date, and that it will cooperate with our new accountants to facilitate a smooth transition. During our two most recent fiscal years and any subsequent interim period through the date of resignation, there were (i) no disagreements with TAAD on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedure, which disagreements, if not resolved to TAAD's satisfaction, would have caused TAAD to make reference to the subject matter of such disagreements in its reports, and (ii) no reportable events as defined in Item 304(a)(1)(v) of Regulation S-K. We provided TAAD with a copy of the disclosures in this Current Report on Form 8-K prior to its filing with the Securities and Exchange Commission ("SEC") and requested that TAAD furnish a letter addressed to the SEC stating whether it agrees with the statements made herein. A copy of such letter is filed as an exhibit to this Current Report on Form 8-K.
02 Departure of Directors or Certain Officers; Election of
ITEM 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Directors or Certain Officers; Compensatory Arrangements of Certain Officers. Effective August 7, 2025, the following individuals resigned from all positions held with the Company, including as officers and/or directors, as applicable: Mr. Lin Jer-Li Mr. Chen YenXun Mr. Chu Pao-Chi Mr. Kao Cheng-Hsiang The resignations were not the result of any disagreement with us on any matter relating to our operations, policies, or practices. Effective the same date, the Board of Directors appointed Dr. Ssu-Chuan Lai, Ph.D., to serve as Chairperson of the Board, Chief Executive Officer, and Chief Financial Officer of the Company. Dr. Lai holds a Ph.D. in Medical Science from Taipei Medical University, as well as M.S. and B.S. degrees in Physical Therapy from China Medical University and Tzu Chi University, respectively. She has over a decade of experience spanning biomedical research, clinical rehabilitation, and cell manufacturing operations. Since 2023, Dr. Lai has served as Vice General Manager of the Cell Manufacturing Division at Biospring Medical Co., Ltd., where she led the setup and management of a 660+ m GTP/GMP-compliant cell manufacturing center. In this role, she oversaw cross-functional teams, ensured compliance with GTP, GMP, and ISO 17025 standards, and facilitated the transition of research projects into scalable, manufacturing-ready pipelines. Previously, Dr. Lai held positions as Senior Engineer in the same division and as a Ph.D. Research Assistant at Taipei Medical University, focusing on stem cell and tissue engineering research for translational projects. She also has clinical experience as a licensed physical therapist in Taiwan. Dr. Lai has completed full training in ISO 17025 Quality Management, Good Manufacturing Practice (GMP), and Good Tissue Practice (GTP), and is recognized for her expertise in facility setup, regulatory-compliant manufacturing,
01. Financial Statements and Exhibits
ITEM 9.01. Financial Statements and Exhibits. 16.1 Letter from TAAD LLP, dated August 11, 2025, regarding change in certifying accountant . 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 2
Forward-Looking Statements
Forward-Looking Statements This current report on Form 8-K contains forward-looking These statements are subject to risks and uncertainties that may cause actual results to differ materially. We undertake no obligation to update any forward-looking statements unless required by law.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunder duly authorized. Date: August 11, 2025 VITASPRING BIOMEDICAL CO. LTD. By: /s/ Ssu-Chuan Lai Name: Ssu-Chuan Lai Title: Chairperson, Chief Executive Officer, and Chief Financial Officer 3